TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6364333
Drug: Metronidazole (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (250 mg, 4 times daily, for one week)
Study: 27112810
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (CT) with computerized cognitive rehabilitation and right hemifield eye-patching, 15 one-hour sessions
Study: 27112810
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment (ST) with computerized cognitive rehabilitation, 15 one-hour sessions
Study: 26009783
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy consisting of exposure and ritual prevention (EX/RP)
Study: 22211956
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg
Study: 15839922
Drug: Alfuzosin 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 15 mg
Study: 10333052
Drug: Reference group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference group without antihypertensive treatment (group 3, n = 9)
Study: 30829116
Drug: Decliners of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decliners of the HPV vaccine
Study: 26980340
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg once daily celecoxib
Study: 26980340
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg once daily celecoxib
Study: 26980340
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg three times daily diclofenac
Study: 25053766
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy Group (MTG)
Study: 18270762
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with intravenous injection of 5 mg/kg of hematoporphyrin monomethyl ether followed by endoscopic irradiation for 40 min at 150 mW/cm².
Study: 18270762
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no photodynamic therapy).
Study: 15017018
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous (IV) and intra-arterial (IA) rt-PA treatment (0.6 mg/kg IV rt-PA, maximum 60 mg over 30 minutes, plus additional rt-PA via microcatheter up to 22 mg over 2 hours)
Study: 15017018
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous (IV) and intra-arterial (IA) rt-PA treatment
Study: 10792277
Drug: Continuous chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous chlorambucil (0.1 mg/kg/d for 7 days, repeated every 6 weeks)
Study: 10792277
Drug: Intermittent chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent chlorambucil (0.3 mg/kg/d for 7 days, repeated every 6 weeks)
Study: 3530649
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg orally)
Study: 20922415
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (250 mg twice a day for 10 days)
Study: 20922415
Drug: Metronidazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (30 mg/kg twice daily for 10 days)
Study: 19773535
Drug: Repaglinide administered
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide administered 1 hour after last gemfibrozil dose
Study: 19773535
Drug: Repaglinide administered
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide administered 24 hours after last gemfibrozil dose
Study: 19773535
Drug: Repaglinide administered
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide administered 48 hours after last gemfibrozil dose
Study: 19773535
Drug: Repaglinide administered
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide administered 96 hours after last gemfibrozil dose
Study: 19773535
Drug: Repaglinide metabolism
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide metabolism inhibition continued up to 48 hours after gemfibrozil administration
Study: 14659717
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment on normal enamel powder
Study: 14659717
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment on NaClO-treated enamel powder
Study: 9549661
Drug: Pyridostigmine bromide
Normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine bromide 30 mg every 8 hours
Study: 3184782
Drug: 4-mg nicotine
Normalized name: nicotine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mg nicotine chewing gum
Study: 28032482
Drug: Edoxaban 15
Normalized name: edoxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 15 mg, once daily
Study: 22047812
Drug: Lobeglitazone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeglitazone 0.5 mg (1 subject placebo)
Study: 22047812
Drug: Lobeglitazone 1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeglitazone 1, 2, 4, and 8 mg (8 subjects in each group, including 2 receiving placebos)
Study: 22047812
Drug: Lobeglitazone 1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeglitazone 1, 2, and 4 mg (once daily for 7 days, 8 subjects in each group, including 2 receiving placebos)
Study: 22047812
Drug: Lobeglitazone (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeglitazone (various doses)
Study: 16388508
Drug: First screening
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First screening round with PSA>or=3.0 ng/ml
Study: 16388508
Drug: Repeat screening
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat screening round with PSA>or=3.0 ng/ml
Study: 8349825
Drug: lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin (40 mg b.i.d.) + low cholesterol diet (mean 246 mg/d)
Study: 8349825
Drug: lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin (40 mg b.i.d.) + high cholesterol diet (mean 1,071 mg/d)
Study: 2872813
Drug: Terazosin (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (5, 10, or 20 mg once daily for four weeks)
Study: 2872813
Drug: Terazosin (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (dose titration until maximum 20 mg)
Study: 2872813
Drug: Prazosin (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (dose titration until maximum 20 mg)
Study: 26231610
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium bicarbonate therapy for 24 months
Study: 21145041
Drug: MK-0777 3
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0777 3 mg b.i.d. (n = 18)
Study: 21145041
Drug: MK-0777 8
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0777 8 mg b.i.d. (n = 21)
Study: 11077134
Drug: Captopril (6.25-12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (6.25-12.5 mg)
Study: 11077134
Drug: Losartan (12.5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (12.5-25 mg)
Study: 9272365
Drug: DTwP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwP vaccine
Study: 29230548
Drug: cis100 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis100 + RT (conventional radiotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43)
Study: 29230548
Drug: cis40 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis40 + ART (accelerated radiotherapy with cisplatin weekly 40 mg/m2)
Study: 25460855
Drug: Amiodarone discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone discontinuation (group 1)
Study: 25460855
Drug: No amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: No amiodarone discontinuation (group 2)
Study: 24159603
Drug: ACTH gel
Normalized name: ACTH Gel
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH gel (16 units)
Study: 24159603
Drug: ACTH gel
Normalized name: ACTH Gel
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH gel (32 units)
Study: 21390311
Drug: Favorable SNP
Normalized name: SNP-ACTH (1-39)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Favorable SNP variants (CC, AA, TT)
Study: 21390311
Drug: IP-10 below
Normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP-10 below 150 pg/mL among genotype 1 infected carriers of favorable alleles
Study: 8760715
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test (100 g)
Study: 6347995
Drug: Misonidazole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misonidazole 2.5 gm/m2 once a week for six weeks (total dose 15 gm/m2) plus radiotherapy (5100 cGy over 6 weeks)
Study: 6347995
Drug: Conventional radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional radiation therapy (6000 cGy/6-7 weeks) plus BCNU (80 mg/m2 on days 3, 4, 5, repeated q 8 weeks for 2 years)
Study: 3469101
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg slow-release formulation of diclofenac sodium
Study: 28895878
Drug: Oat betaglucans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat betaglucans (1.53 g of β‐glucan) administered three times daily before meals for two weeks
Study: 28895878
Drug: Placebo (Plac)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Plac) administered three times daily before meals for two weeks
Study: 21396122
Drug: Problem solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem solving therapy
Study: 25927191
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of interventions
Study: 18478129
Drug: Intravenous moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous moxifloxacin (400 mg daily) for 5 days starting within 36 hours after stroke onset
Study: 18478129
Drug: Intravenous moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous moxifloxacin (400 mg daily) for 5 days
Study: 18478129
Drug: Intravenous moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous moxifloxacin (400 mg daily)
Study: 16509866
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment for 72 weeks (group C)
Study: 10821722
Drug: Bambuterol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol (10 mg oral solution once daily)
Study: 10821722
Drug: Terbutaline (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (0.075 mg/kg oral solution three times daily)
Study: 8994466
Drug: PCA (patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA (patient-controlled intravenous opioid analgesic administration)
Study: 8398438
Drug: Co-amoxiclav (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (250 mg amoxycillin plus 125 mg clavulanic acid, eight-hourly)
Study: 8398438
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (250 mg phenoxymethylpenicillin, six-hourly)
Study: 3510944
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with chlorambucil and cisplatin
Study: 3510944
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with chlorambucil and cisplatin
Study: 3510944
Drug: Second-line treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line treatment with cisplatin after initial chlorambucil failure
Study: 27052296
Drug: Whole-brain radiotherapy
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-brain radiotherapy combined with sodium glycididazole at a dose of 700mg/m² intravenous infusion 30 minutes before radiotherapy, three times a week
Study: 16390366
Drug: 0.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/day omega-3 fatty acids
Study: 16390366
Drug: 1.4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 g/day omega-3 fatty acids
Study: 16390366
Drug: 2.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.8 g/day omega-3 fatty acids
Study: 10994618
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication treatment (n = 10)
Study: 4006647
Drug: ursodeoxycholic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ursodeoxycholic acid, 800 mg/day
Study: 4006647
Drug: ursodeoxycholic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ursodeoxycholic acid, 400 mg/day
Study: 4006647
Drug: chenodeoxycholic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: chenodeoxycholic acid, 750 mg/day
Study: 4006647
Drug: chenodeoxycholic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: chenodeoxycholic acid, 375 mg/day
Study: 30930022
Drug: GS-4774 (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-4774 (2, 10, or 40 yeast units) with Tenofovir Disoproxil Fumarate (TDF) 300 mg daily
Study: 7526067
Drug: intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous placebo
Study: 21877761
Drug: Ipragliflozin (ASP1941),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin (ASP1941), doses ranging from 5-600 mg, administered once daily for 10 days
Study: 19236490
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive craniopuncture therapy
Study: 16552540
Drug: Topical Licochalcone
Normalized name: Licochalcone A
DrugBank: Licochalcone A (DB19281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Licochalcone A (LicA)
Study: 12940503
Drug: D-cycloserine (0-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (0-500 mg/70 kg, per os)
Study: 12940503
Drug: D-cycloserine (0-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (0-500 mg/70 kg, per os) combined with naloxone (0.15 mg/70 kg, intramuscularly)
Study: 12940503
Drug: Naloxone (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.15 mg/70 kg, intramuscularly)
Study: 1549149
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (10 mg/m²)
Study: 1549149
Drug: Very-low-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Very-low-dose methotrexate (5 mg/m²)
Study: 3983884
Drug: Theophylline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (10 mg/ml)
Study: 3983884
Drug: Glycine theophyllinate
Normalized name: Theophylline Sodium Glycinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine theophyllinate (50 mg/ml)
Study: 3983884
Drug: Aminophylline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (50 mg/ml)
Study: 3983884
Drug: Diprophylline (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprophylline (125 mg/ml)
Study: 3983884
Drug: Salbutamol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (200 micrograms from a metered dose inhaler)
Study: 27497474
Drug: Cognitive Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Stimulation (CS) program, twice weekly for eight weeks (EG; n=36)
Study: 18159575
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine 3 mg + morphine 50 microg
Study: 18159575
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine 3 mg + morphine 100 microg
Study: 15513449
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone sodium succinate (1 gram IV/day for 3 days) followed by oral prednisone (1 mg/kg/day for 11 days) with 4‐day taper (20 mg on day 1, 10 mg on days 2 and 4)
Study: 15513449
Drug: Interferon beta
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta 1‐a (Avonex 30microg intramuscularly [IM] weekly, or Rebif 22 microg subcutaneously [SQ] weekly)
Study: 15513449
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone alone, without prior treatment with IV methylprednisolone
Study: 15513449
Drug: IV methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV methylprednisolone treatment followed by oral prednisone
Study: 9537209
Drug: Diflunisal 500
Normalized name: diflunisal 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal 500 mg perorally twice a day for 7 days
Study: 9537209
Drug: Dipyrone 500
Normalized name: dipyrone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 500 mg perorally three times a day for 7 days
Study: 9398952
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg physostigmine
Study: 1760167
Drug: IM ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM ranitidine 1 mg/kg (n = 15)
Study: 1760167
Drug: IM ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM ranitidine 2 mg/kg (n = 15)
Study: 6114900
Drug: Pirenzepine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (0.15 mg/kg) plus ranitidine (0.6 mg/kg)
Study: 23114134
Drug: Bisphosphonates combined
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonates combined with chemotherapy
Study: 19208456
Drug: Tat vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tat vaccine (7.5microg, 15microg, or 30microg doses)
Study: 17595890
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg ER (evening)
Study: 17595890
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg ER (morning)
Study: 17595890
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg ER (morning and evening)
Study: 15823775
Drug: Travoprost 0.004%
Normalized name: TRAVOPROST 0.004% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travoprost 0.004% ophthalmic solution (opened group)
Study: 15823775
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sealed travoprost 0.004% ophthalmic solution)
Study: 11590531
Drug: Newer drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer drugs in the NRTI class and nucleotide RT inhibitors
Study: 11590531
Drug: Drug resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug resistance testing
Study: 8509233
Drug: Alfacalcidol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (6 micrograms daily for 6 months)
Study: 31728713
Drug: Patisiran 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran 0.3 mg/kg intravenously once every 3 weeks for 18 months
Study: 29606543
Drug: ASP7991 [1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP7991 [1 mg, 18.5 kBq (500 nCi)]
Study: 24469862
Drug: Low-dose control
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose control (audiobooks)
Study: 16003451
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy (simvastatin) for primary prevention in individuals with TC level higher than 6.2 mmol/L
Study: 16003451
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy (simvastatin) for secondary prevention in individuals with TC level higher than 6.2 mmol/L
Study: 16003451
Drug: Lipid-lowering treatment
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering treatment for all individuals with TC level higher than 6.2 mmol/L
Study: 16003451
Drug: Lipid-lowering treatment
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering treatment for all individuals regardless of TC levels
Study: 12204809
Drug: atorvastatin 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 20, 40, and 80 mg/day
Study: 12204809
Drug: simvastatin 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 20, 40, and 80 mg/day
Study: 12204809
Drug: pravastatin 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin 20, 40, and 80 mg/day
Study: 12204809
Drug: lovastatin 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin 20, 40, and 80 mg/day
Study: 12204809
Drug: fluvastatin 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluvastatin 20, 40, and 80 mg/day
Study: 8631045
Drug: Cilazapril 2.5-5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 2.5-5.0 mg per day
Study: 1671389
Drug: Met-GH infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Met-GH infusion (80 ng/kg.min)
Study: 27321488
Drug: Ulinastatin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin treatment (8×10^5 U, twice a day for 7 days)
Study: 22270199
Drug: Moisturizing lotion
Normalized name: MOISTURIZING LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moisturizing lotion (Eucerin Lotion)
Study: 19497591
Drug: BC +
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BC + 5 mg propranolol
Study: 19497591
Drug: BC +
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BC + 10 mg propranolol
Study: 15700851
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with vincristine (VCR), methotrexate (MTX), and doxorubicin (ADM)
Study: 7915824
Drug: Cabergoline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.5 to 1.0 mg twice weekly)